click below
click below
Normal Size Small Size show me how
Endocrine 1
BDK
| Pharmacologic Category | Generic Name | Brand Name | Common Indication | Essential Knowledge |
|---|---|---|---|---|
| Biguanide | metformin | Fortamet, Glumetza | Type 2 DM, PCOS | KSE: diarrhea, nausea, vomiting, vitamin b12 deficiency. ON: CI with eGFR <30. BBW: lactic acidosis |
| Dipeptidyl peptidase (DPP-4) inhibitor | sitagliptin | Januvia, Zituvio | Type 2 DM | KSE: nasopharyngitis |
| Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | empagliflozin | Jardiance | Type 2 DM, HF, CKD | KSE: genital mycotic infections, UTI |
| Sulfonylurea | glimepiride | Amaryl | Type 2 DM | KSE: hypoglycemia, weight gain |
| Sulfonylurea | glipizide | Glucotrol, Glucotrol XL | Type 2 DM | KSE: hypoglycemia, weight gain |
| Thiazolidinedione (TZD) | pioglitazone | Actos | Type 2 DM | KSE: peripheral edema, weight gain, URI, increased risk of fractures and bladder cancer. BBW: may be exacerbate CHF and CI in NYHA Class III and IV |
| Glucagon-like peptide-1 (GLP-1) receptor agonist | liraglutide | Victoza, Saxenda | Type 2 DM, chronic weight management | KSE: nausea, vomiting, diarrhea, pancreatitis. BBW: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer |
| Insulin, long acting | insulin glargine | Lantus, Toujeo, Basaglar | Type 1 & 2 DM | KSE: hypoglycemia, weight gain |
| Insulin, intermediate acting | insulin NPH | Humulin N, Novolin N (OTC) | Type 1 & 2 DM | KSE: hypoglycemia, weight gain |
| Insulin, rapid acting | insulin aspart | Novolog | Type 1 & 2 DM | KSE: hypoglycemia, weight gain |
| Insulin, rapid acting | insulin lispro | Humalog | Type 1 & 2 DM | KSE: hypoglycemia, weight gain |
| Insulin, short acting | insulin regular | Humulin R, Novolin R | Type 1 & 2 DM, DKA | KSE: hypoglycemia, weight gain |
| Sodium-glucose cotransporter inhibitor 2 (SGLT2 inhibitor) | dapagliflozin | Farxiga | Type 2 DM, HF, CKD | KSE: genital mycotic infections, UTI |
| Glucagon-like peptide 1 (GLP-1) receptor agonist | dulaglutide | Trulicity | Type 2 DM | KSE: nausea, vomiting, diarrhea, constipation, pancreatitis. BBW: may increase risk of thyroid c-cell tumor |
| Glucagon-like peptide 1 (GLP-1) receptor agonist | semaglutide | SQ: Ozempic, Wegovy PO: Rybelsus | Type 2 DM, chronic weight management | KSE: nausea, vomiting, diarrhea, constipation, pancreatitis. BBW: may increase risk of thyroid c-cell tumor, CI in personal or family history of medullary thyroid cancer |
| Dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist | tirzepatide | Mounjaro, Zepbound | Type 2 DM, chronic weight management | KSE: nausea, vomiting, diarrhea, constipation, increased heart rate, pancreatitis. BBW: may increase risk of thyroid c-cell tumor |